Bence Jones Proteins Bind to a Common Peptide Segment of Tamm-Horsfall Glycoprotein to Promote Heterotypic Aggregation

Zhi-Qiang Huang, Katherine A. Kirk, Kevin G. Connelly, and Paul W. Sanders
Nephrology Research and Training Center, Division of Nephrology, Departments of Medicine, Physiology, and Biostatistics and Biomechanics, University of Alabama at Birmingham, and Veterans Affairs Medical Center, Birmingham, Alabama 35292

Abstract

Bence Jones proteins (BJPs) are the major pathogenic factor causing cast nephropathy ("myeloma kidney") by coaggregation with Tamm-Horsfall glycoprotein (THP). Understanding the interaction between these proteins is therefore important in developing treatment strategies to prevent renal failure from cast formation in multiple myeloma. We developed an enzyme-linked immunoassay to examine this phenomenon. Five different human BJPs (four k and one l immunoglobulin light chains) were used in this assay that demonstrated these proteins bound THP with different affinity. BJPs competed among themselves for binding to THP. The binding site was a peptide portion of THP since these proteins also bound deglycosylated THP. Also, one monoclonal antibody directed against a peptide segment of human THP prevented binding of THP to BJPs. By altering the conformation of THP, reducing agents decreased binding between these two proteins in concentration-dependent fashion. In turbidity studies, the monoclonal antibody that prevented binding and a reducing agent, dithiothreitol, decreased coaggregation. Deglycosylated THP did not coaggregate with BJPs. We concluded that ionic interaction between BJPs and a specific peptide binding site on THP promoted heterotypic coaggregation. The carbohydrate moiety of THP was also essential for coaggregation, perhaps by facilitating homotypic aggregation of THP. (J. Clin. Invest. 1993. 92:2975–2983.) Key words: renal failure • Bence Jones proteins • Tamm-Horsfall glycoprotein • reducing agents • multiple myeloma

Introduction

About half of patients presenting with multiple myeloma have concomitant renal insufficiency usually related to Bence Jones proteinuria (1–3). While a variety of renal lesions are associated with multiple myeloma (4), cast nephropathy, or "myeloma kidney," is perhaps best recognized and most common (5, 6). Using microdissection techniques, Oliver (7) demonstrated large numbers of casts obstructing tubule lumens of patients who died from myeloma and renal failure, hence the term cast nephropathy. These intraluminal casts are composed of Bence Jones protein (BJP)1 and Tamm-Horsfall glycoprotein (THP) (8), a protein that is synthesized by cells of the thick ascending limb of the loop of Henle (9, 10) and is the major constituent of urinary casts (11). As shown originally by Koss et al. (12) and confirmed by others (13–19), cast nephropathy can be reproduced in mice and rats by parenteral injection of purified human Bence Jones protein. We have demonstrated that cast-forming human Bence Jones proteins coaggregate with Tamm-Horsfall glycoprotein to obstruct the distal nephron (14–16). In addition, intravenous infusion of nephrotoxic human Bence Jones protein in rats elevates proximal tubule pressure and simultaneously decreases single nephron glomerular filtration rate; intraluminal protein casts were identified in these kidneys (18). Thus, intraluminal obstruction from cast formation appears to be a prominent cause of the acute renal failure in multiple myeloma. Because of the central role of Bence Jones proteins and Tamm-Horsfall glycoprotein in renal failure from cast nephropathy, our current study examines in detail the binding interaction between these proteins. Characterization of this interaction allows development of new therapies that focus specifically on this basic pathogenic mechanism of cast nephropathy and may serve to decrease morbidity and mortality from renal failure in multiple myeloma.

Methods

Protein preparation. Five different BJPs were used in these studies. BJPKap, BJPcry, and BJPd0 were purified from the urine of patients who had multiple myeloma and renal failure using techniques described previously (20). These proteins corresponded to those proteins (previously referred to as BJP1, BJP2, and BJP3, respectively) used in previous studies (14, 15). Because of the relative abundance of these proteins and the requirement of large amounts of protein in some experiments, these three BJPs were used in the majority of studies. BJPon was from a patient who had no clinical evidence of renal dysfunction, although under conditions of mild depletion of extracellular fluid volume, this protein obstructed the rat distal nephron (16). BJPtryp was from a patient who had renal failure and histopathologic evidence of cast nephropathy. These two proteins were generous gifts from Dr. Alan Solomon (University of Tennessee Medical Center, Knoxville, TN). All BJPs except BJPd0 were kappa light chains. THP was purified from the urine of a normal male volunteer in standard fashion (15) by precipitation with NaCl, 0.64 M, followed by centrifugation at 48,000 g for 15 min. The pellet was resuspended with deionized water, then dialyzed against deionized water for 72 h. The protein was lyophilized and stored at −20°C. Electrophoresis of this product using a 7.5% polyacrylamide gel (SDS-PAGE) demonstrated a single band at ~100 kD.

---

Footnotes:

1. Abbreviations used in this paper: BJP, Bence Jones protein; THP, Tamm-Horsfall glycoprotein.


Address correspondence to Paul W. Sanders, M.D., Division of Nephrology/Department of Medicine, 642 Lyons-Harrison Research Building, University of Alabama at Birmingham, Birmingham, AL 35292-0007.

Received for publication 7 December 1992 and in revised form 16 July 1993.

The Journal of Clinical Investigation, Inc.
Volume 92, December 1993, 2975–2983
Western blotting using rabbit polyclonal antiserum against human THP (Biomedical Technologies Inc., Stoughton, MA) confirmed the identity of this band as THP.

Several experiments used deglycosylated THP, which was prepared by dissolving THP, 10 mg/ml, in 1% SDS (Bio-Rad Laboratories, Richmond, CA), boiling for 5 min, then mixing in sodium phosphate buffer, pH 8.6, containing 100 mM sodium phosphate, 5 mM l, 10-

phenantherol, 0.3% Triton X-100, and 100 U/ml N-glycosidase F (PNGase F; Boehringer Mannheim Biochemical, Indianapolis, IN). The final concentration of THP was 0.5 mg/ml. The mixture was incubated at 37°C for 18 h. After the incubation, the buffer was changed to 1% Tween 20 in PBS with at least three buffer exchanges using a microcentrifuge (Cenetricon 30; Amicon, W. R. Grace Co., Beverly, MA). Deglycosylated THP was then aliquoted and stored at −20°C. Successful deglycosylation of THP was confirmed using a glycan detection kit (Boehringer Mannheim Biochemical), which detects the presence of carbohydrate with as little as 10 ng of glycoprotein.

A mouse monoclonal antibody against purified human THP was raised in our laboratory and purified from the medium using ammonium sulfate precipitation and a protein G column (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). To determine whether this monoclonal antibody reacted with the peptide portion of THP, THP and deglycosylated THP underwent electrophoresis (SDS-PAGE) using a 12% polyacrylamide gel. After transfer of these proteins onto nitrocellulose and washing in standard fashion, the membrane was incubated with our mouse anti-human THP monoclonal antibody, followed by rabbit anti-mouse IgG antibody conjugated with horseradish peroxidase (Bio-Rad, Melville, NY). After additional washes, the membrane was developed using peroxidase substrate (0.1 mM Tris/HCl, pH 7.4, 0.8 mg/ml 3,3′-diaminobenzidine, 0.01% hydrogen peroxide).

**Binding analysis studies.** To characterize the binding of THP with BJPs, an enzyme-linked immunobassay was developed. In these and subsequent studies that compared binding of the various BJPs to human THP, all five proteins were examined simultaneously on the same microplate. Wells of microplates were coated with BJPs, 2 µg/ml in PBS, pH 7.4, and incubated overnight at room temperature. The wells were washed three times with 0.05% Tween 20 in PBS. The remaining unoccupied binding sites in the wells were blocked by incubating with 1% BSA in PBS for 1 h at room temperature. Native THP or deglycosylated THP, suspended in 1% Tween 20 in PBS, was added to the wells (100 µl/well) after additional washes with 0.05% Tween 20 in PBS. The microplates were incubated for 30 min at room temperature. Polyclonal rabbit antibody against human THP, 1:3,000 dilution in PBS, was added to the wells, followed by horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (Bio-Rad, Melville, New York), 1:1,000 dilution in PBS. Microplates were incubated with the same data.

After washing the microplates, 3,3′-diaminobenzidine, 0.01% hydrogen peroxide was added to the wells, followed by peroxidase substrate. Optical density was determined at 405 nm using a microplate reader (THERMOrax, Molecular Devices Corporation).

In a separate experiment, wells of microplates were coated with THP, 2 µg/ml, overnight at room temperature. After blocking and washing, each bacterioid BLP, 0–300 µg/ml, was added to the wells, which were incubated for 30 min at room temperature. After extensive washes, streptavidin-conjugated horseradish peroxidase, 1:3,000 dilution in PBS, was added to the wells, followed by peroxidase substrate. Optical density was determined at 405 nm using a microplate reader.

**Effects of reducing agents.** To define further the binding interaction between BJ and THP, we included reducing agents in our binding assay. After coating wells of microplates with a test BJ and washing and blocking as described above, 50 µl 10-Mercaptoethanol, 250 mM, was added to the wells, followed by 50 µl THP, 300 µg/ml. The plate was shaken once and incubated for 30 min at room temperature. Other reducing agents, including cysteamine, penicillamine, dithiobiotitotiole, L-cysteine, and N-acetyl-L-cysteine were also tested in this fashion in doses between 0 and 300 mM using BLP, BLP and BLP. Two closely related compounds, cysteamine, and cysteamine phosphate, 0–300 µM, were used as controls because they did not possess free sulfhydryl groups and therefore did not serve as reducing agents. In a separate experiment, after incubating wells that contained the five BJPs with THP for 30 min at room temperature, 10-Mercaptoethanol, 250 mM, was added after washing, and wells were incubated another 10 min. After extensive washing, THP bound on the wells was detected as described above. The amount of reducing agent required to inhibit binding of THP by 50% (ED50) was calculated from these data.

To observe whether BJ and THP possessed free sulfhydryl groups through which binding may have occurred, 20 µl of BLP, BLP and BLP, 1 mM in PBS, pH 7.4, were mixed with 100 µl 5,5′-dithiobis(2-nitrobenzoic acid) (Ellman’s reagent; Caymam Chemical Co., Inc., Ann Arbor, MI) in a microplate and incubated for 30 min at room temperature. N-Acetyl-L-cysteine was used as a positive control. Optical density was read at 405 nm using a microplate reader. In a separate experiment, BLP, 1 mg/ml, was incubated with 1 mM and 10 mM iodoacetamide, a potent thiol-blocking agent. These treated BLP preparations were diluted to 2 µg/ml and used to coat the wells of microplates. Binding assay was performed as described above and compared to binding reaction between THP and untreated BLP.

To examine whether reducing agents affected directly either BJ or THP, wells of microplates were coated with BLP, BLP, and THP, 2 µg/ml, and were washed and blocked as described. Dithiobiotitotiole, 0–100 mM, was added to the wells and incubated for 30 min at room temperature. After extensive washing with 0.05% Tween 20 in PBS, THP, 150 µg/ml, was added to the wells treated with BLP followed by rabbit anti-human THP and goat anti-rabbit IgG antibody conjugated with horseradish peroxidase. BLP, BLP, and BLP, 1 mg/ml, were added to the wells coated with THP followed by goat anti-κappa and anti-lambda light chain antibodies (Oyganon Teknika, West Chester, PA) and rabbit anti-gamma IgG antibody conjugated with horseradish peroxidase (Bio-Rad, Melville, NY). The plates were
washed again and developed using the same substrate. Optical density was read at 405 nm.

**Competition studies.** To determine whether different BJPs bound to the same site on THP, wells of microplates were coated with the five BJPs, 2 µg/ml in PBS, and incubated overnight at room temperature. After washing with 0.05% Tween 20 in PBS and blocking with 1% BSA in PBS for 30 min, 50 µl of BSA or BJPs, BJs, and BJDs, 0.02–60 mg/ml, was added to the wells, followed by 50 µl THP, 300 µg/ml. The plates were shaken to mix THP and BJPs thoroughly and incubated for 30 min at room temperature. After extensive washing, THP bound to wells was determined as described above.

In other experiments, our mouse monoclonal anti-human THP antibody, 0.1–33 µg/ml, was used as a competitor in this binding assay. Another commercial mouse monoclonal anti-human THP antibody was purified from mouse ascitic fluid (Accurate Chem. & Sci. Corp., Westbury, NY) using 50% ammonium sulfate precipitation and a THP-conjugated Sepharose 4B (Sigma Chemical Co.) affinity column. Final antibody concentration was adjusted to 33 µg/ml before use. BSA served as a control in these experiments.

Finally, because human THP contains an RGD (arginine-glycine-aspartic acid) peptide sequence (10, 22) which is a common binding site for adhesion molecules (23), we used a synthesized RGD peptide (Bachem California, Torrance, CA), 0.0075–2.5 mg/ml, as a competitor in these studies.

**Turbidity measurements.** As described previously (15, 16), to observe coaggregation of THP with BJPs in vitro, turbidity of solutions containing THP and deglycosylated THP, 0.125 µg/ml in PBS, pH 7.4, was determined using a spectrophotometer (M-series; Photon Technology International, Inc., South Brunswick, NJ) at an excitation and monitoring wavelength of 488 nm. After confirming a stable baseline, change in turbidity was determined after adding BJPs, BJs, and BJD, 0.06 mg/ml. These concentrations of proteins were used because they reflected the relative amounts and ratios of these proteins found in the distal nephron. Furthermore, they were identical to those used previously (16). These protein ratios differed from those used in the initial binding analysis studies but were similar to those experiments that used biotinylated BJPs. In other studies, THP was preincubated with our monoclonal anti-human THP antibody, 3.5 µg/ml, and change in turbidity after addition of BJs was monitored. To observe the effect of reducing agents on the coaggregation, changes in turbidity of THP-containing solutions were monitored after addition of dithiothreitol, 1.5 mM.

**Statistical analysis.** Two statistical models were used to estimate parameters of interest in the binding analysis studies. The first was a two-parameter, cumulative negative exponential with the parameters being a maximum response and either an initial slope or the EC50 as desired. The second was a logistic model in which the logarithm of the concentration was the independent variable. This model is well suited to binders that do not deviate from the model in the nonlinear least squares procedure (NLLN) of the Statistical Analysis System (SAS Institute, Inc., Cary, NC). This method produces estimated standard errors for the parameter estimates and 95% confidence interval estimates of the parameters. The two-parameter model appeared to be adequate to describe the association curves; dose response and competition curves more often required the logistic.

**Results**

**Binding analyses.** All five BJPs bound THP; these interactions displayed saturation kinetics (Figs. 1 and 2). These BJPs presented varying binding affinities and initial binding rates to THP (Table 1). BJPs and BJrh most avidly, while BJs and BJln had the lowest affinities (Figs. 1 and 2). Using biotinylated BJPs, binding of the BJPs to wells of microplates did not differ (Fig. 3). Therefore, efficiency of coating wells of microplates was not a variable in these and subsequent studies that used microplates coated initially with BJs. Experiments that examined binding of biotinylated BJPs to THP-coated wells also showed results comparable to the initial binding studies, with BJs, BJps, and BJD demonstrating high binding affinities for THP, and BJs and BJln low affinities.

![Figure 1](http://www.jci.org) **Figure 1.** Effect of increasing concentrations of THP on binding to BJPs (n = 5 experiments). In these experiments, the wells had been coated with the test BJs, 2 µg/ml, and THP, 0–1,000 µg/ml, was added subsequently. Data from each experiment were standardized by making the maximum optical density for each experiment equal to 100%. As indicated by the initial slopes of the curves, the affinities of BJPs to THP varied. BJs and BJs had the highest affinities to THP, while BJs and BJs had the lowest (Table 1).

![Figure 2](http://www.jci.org) **Figure 2.** Time course of THP binding to BJPs (n = 5 experiments). A constant amount of THP, 150 µg/ml, was added to wells coated with BJs, 2 µg/ml. Data from each experiment were standardized by making the maximum optical density for each experiment equal to 100%. Initial binding rates of these proteins to THP differed and are shown in Table I. Again, BJs and BJs had the highest initial slopes, BJs and BJs had the lowest.
Table I. Half-maximal Binding Concentration (EC50) and Initial Binding Rates of THP with Each of the Five BJPs

<table>
<thead>
<tr>
<th>Protein</th>
<th>BJPry</th>
<th>BPmiC</th>
<th>BPdon</th>
<th>BPapr</th>
<th>BPem</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC50, nM</td>
<td>8.9±0.5</td>
<td>13.8±2.3</td>
<td>17.9±2.2</td>
<td>144.5±24.9</td>
<td>363.0±19.1</td>
</tr>
<tr>
<td>Initial binding rate, % bound per min</td>
<td>36.3±2.5</td>
<td>21.6±3.1</td>
<td>11.1±1.2</td>
<td>1.7±0.2</td>
<td>0.2±0.0</td>
</tr>
</tbody>
</table>

(data not shown). Deglycosylated THP also bound to all five BJPs in a fashion similar to native THP (Fig. 4).

Reducing agents inhibited binding of THP to BJPs in a dose-dependent fashion. Dithiothreitol was the most potent inhibitor (Table II). Cystamine and cysteamine-S-phosphate, two compounds that did not contain free sulfhydryl groups, had no effect on the binding of THP to BJPs. Similarly, β-mercaptoethanol decreased binding of THP to BJPs (Fig. 5). After THP bound to BJPs, incubating with this reducing agent also removed bound THP (Fig. 5). Using Ellman’s reagent, free sulfhydryl groups on BJPmic, BJPrap, BPdon, and THP were not detected. When BJPmic, BPrap, and BPdon coated on the wells of microplates were pretreated with dithiothreitol, which was removed before addition of THP, binding of THP was not influenced. In contrast, when THP coated on the wells of microplates was pretreated with dithiothreitol before addition of BJPs, binding of BJPmic, BPrap, and BPdon decreased with increasing doses of dithiothreitol. In these studies, the amount of dithiothreitol required to inhibit the binding of THP by 50% (ED50) was 0.07 mM for BJPmic, 0.7 mM for BPrap, and 0.7 mM for BPdon.

Competition studies. BJPmic, BPrap, and BPdon competed with all five BJPs for binding to THP coated on wells of microplates (Fig. 6). Competition occurred in a dose-dependent fashion. Among the different proteins, competition depended upon the binding affinities of the individual BJP. BJPmic and BPdon had higher affinities for THP and served as stronger competitors than BPrap, which had a low affinity for THP. BSA did not inhibit binding of THP to BJPs. When a mouse monoclonal antibody directed against human THP was used as a competitor, binding between BJPs and THP was inhibited in a dose-dependent manner (Fig. 7). This monoclonal antibody reacted with an epitope on the peptide portion of human THP (Fig. 8). BSA, a commercial monoclonal anti-THP antibody, and the RGD peptide did not decrease binding of THP to BJPs.

Turbidity measurements. BJPmic, BPrap, and BPdon increased turbidity of solutions containing THP. Hairlike particles in these solutions were seen with the naked eye at the end of these tests. In contrast, turbidity did not increase when the BJPs were added to solutions containing deglycosylated THP (Fig. 9). When our monoclonal anti–human THP antibody was preincubated with THP, the increase in turbidity that occurred with BJPmic, BPrap, and BPdon was lessened by 40% (Fig. 10) (n = 4 experiments for each protein). The simultaneous addition of dithiothreitol with BJP to THP-containing solutions reduced the incremental increase in turbidity by 40% (Fig. 11) (n = 4 experiments). Pretreatment of THP with dithiothreitol, 1.5 mM, further reduced subsequent coaggregation with BJP by ~ 80%.

Discussion

By coaggregating with THP in the lumen of the distal nephron, BJPs are the principle pathogenic factor in cast nephropathy, or myeloma kidney (15, 16). The current studies were de-

**Figure 3.** To determine whether binding of the five BJPs to microplate wells differed, solutions containing biotinylated and unbiotinylated BJPs, in a final concentration of 2 μg/ml in PBS, were used to coat wells (n = 12 for each BJP), which were incubated overnight. After washing and blocking, the wells were developed using streptavidin-conjugated horseradish peroxidase and peroxidase substrate. Optical density, which was corrected for degree of biotinylation of each protein (see Methods), did not differ (P = 0.1277) among the five proteins.

**Figure 4.** Binding of either THP or deglycosylated THP, 150 μg/ml, to microwells coated with BJP, 2 μg/ml. Binding affinities between THP and deglycosylated THP did not differ (n = 3 experiments for each group).
Table II. Effect of Reducing Agents on Prevention of Binding of THP to BJPs

<table>
<thead>
<tr>
<th>Reducing agent</th>
<th>Chemical formula</th>
<th>ED_{50} mM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BJPrap</td>
<td>BJPdon</td>
</tr>
<tr>
<td>Cysteamine</td>
<td>HS—CH2—CH2—NH2</td>
<td>22.7±1.8</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>HS—CH—COOH</td>
<td>54.2±16.1</td>
</tr>
<tr>
<td>Dithiothreitol</td>
<td>HS—CH2CHCHCH2—SH</td>
<td>2.4±0.1</td>
</tr>
<tr>
<td>Cysteine</td>
<td>HS—CH2CHCOOH</td>
<td>17.8±1.1</td>
</tr>
<tr>
<td>N-acetyl-cysteine</td>
<td>HS—CH2CHCOOH</td>
<td>57.9±5.3</td>
</tr>
<tr>
<td>Cystamine</td>
<td>S—CH2CHNH2</td>
<td>No effect</td>
</tr>
<tr>
<td>Cysteamine-S-phosphate</td>
<td>PO4—S—CH2CH2NH2</td>
<td>No effect</td>
</tr>
</tbody>
</table>

signed to examine the binding interaction between these proteins. Using an enzyme-linked immunoassay, we found that BJPs bound human THP with different affinities. BJPs competed among each other for binding to THP. A monoclonal antibody directed against a peptide portion of THP served as a competitive inhibitor of binding (Fig. 7). BJPs also bound THP that had been completely deglycosylated enzymatically. These data demonstrated that BJPs bound to a common peptide segment on THP. Reducing agents interacted with THP to prevent subsequent binding to BJPs. In agreement with others (24), Ellman's reagent did not detect free thiol groups on THP, suggesting that the binding interaction between these proteins was not covalent. In turbidity studies, both the monoclonal antibody, which prevented binding of BJ to THP, and the reducing agent, dithiothreitol, decreased heterotypic aggregation. Although deglycosylated THP bound to BJPs, coaggregation with BJPs did not occur. In summary, these combined data demonstrated that BJPs bound through ionic interaction to a common peptide region on THP. This heterotypic aggregation was dependent on this interaction as well as the carbohydrate moiety of THP.

THP is composed of 616 amino acids and has eight potential asparagine-linked glycosylation sites (9, 10, 22). Intramolecular disulfide bonds formed between 48 cysteine residues interspersed throughout the molecule are important in keeping a rigid structure; reducing agents do not dissociate the molecule into smaller subunits (9, 22, 24). The major secondary structure is a β-sheet with a regular zig-zag appearance (9, 25). The carbohydrate component accounts for 30% of the total molecular weight and is responsible for homotypic aggregation which promotes gel formation (9, 25). In the present study, the carbohydrate moiety of THP did not influence the binding efficiency to BJPs, which also bound to deglycosylated THP. Thus, unlike other proteins, such as interleukin-1, which binds to the carbohydrate moiety of THP (10, 26), our data demonstrated that BJP was not a lectinlike protein. Previous work found that colchicine, which decreased carbohydrate content of THP (mainly sialic acid), prevented coaggregation of THP with BJP (16). In our present study, complete deglycosylation of THP also abolished coaggregation. Thus, the carbohydrate moiety was essential in heterotypic aggregation of THP and BJP by allowing simultaneously homotypic aggregation among the molecules of THP (9, 25). Possibly, the binding of BJP to THP also changed the net electric charge on the surface of THP to

![Figure 5. Effect of β-mercaptoethanol on binding between THP and BJPs (n = 3 experiments). In the control groups, THP was added to the wells without β-mercaptoethanol and incubated for 30 min. (A) THP, 150 μg/ml, was added simultaneously with β-mercaptoethanol, 250 mM, to wells coated with BJPs, 2 μg/ml in PBS, and incubated for 30 min. A marked decrease in binding occurred. (B) THP, 150 μg/ml, was added to wells coated with BJP, 2 μg/ml. After 30 min, the wells were washed, then β-mercaptoethanol, 250 mM, was added for 10 min before the plate was washed and developed the plate. β-Mercaptoethanol dissociated the THP–BJP complexes.](http://www.jci.org)
favor coaggregation and subsequent precipitation of the THP-BJP complex.

BJPs represent a family of low molecular weight proteins that are structurally homogeneous, but unique, immunoglobulin light chains (27). As suggested originally by Osserman (28), nephrotoxic potential of BJPs appears to relate to certain physicochemical characteristics of these proteins. However, discerning which property(ies) is important has proved difficult. In the current study, all tested BJPs bound THP, but with differing affinities, which presumably was related to distinct physicochemical properties of the BJPs. In the competition study with BJPs, different BJPs replaced each other despite having different isotypes (κ or λ). Other investigators showed that both κ and λ BJPs deposited as casts in mouse and rat kidneys (13–19, 29). The difference in the binding affinity in the current study was also not related directly to the isoelectric point of BJPs (Table III). For example, two BJPs (BJPmic and BJPrap) that had a similar range of isoelectric points had totally different affinities to THP. In general, however, isoelectric point has been found to be an important determinant of coaggregation because proteins with isoelectric points < 5.1 did not aggregate with THP (15), and cationic BJPs were more nephrotoxic than those BJPs that had lower isoelectric points (13). These data were further supported in a clinical study, which found that those patients that excreted BJPs with isoelectric points > 6.0 had more severe and irreversible renal failure than those patients that excreted more anionic proteins (30). The different affinities to THP may relate to amino acid substitutions in the hypervariable peptide segment, which differentiates those molecules that have highly conserved three-dimensional structures (31). This study did not determine that property or peptide sequence responsible for nephrotoxicity, but has provided a means to study further protein nephrotoxicity; defining these nephrotoxic properties is a future direction of this laboratory.

The primary cause of cast formation in myeloma kidney is filtered BJP from the blood stream (12–19). In a previous study, we showed that BJPmic, BJPrap, and BJPdon aggregated with THP in vitro. BJPmic was most potent in causing aggregation, while BJPrap was the weakest (15). These data were consistent with the binding affinities of these three BJPs to THP in the current study (Figs. 1 and 2). Thus, binding affinity was closely related to heterotypic aggregation. Because the binding affinity of BJP to THP correlated with aggregation, this characteristic of BJP appeared to be a basic criterion for cast formation. While binding of BJP to THP may be considered a risk factor promoting cast nephropathy in patients with multiple myeloma and Bence Jones proteinuria, more studies are re-
required before the kinetics of binding determined by ELISA may be used as a clinical tool. Cast formation is also related to other factors, such as pH and ion concentrations in the distal tubular fluid, extracellular fluid volume, use of loop diuretics, hypercalcemia, and concentrations of BJP and THP in the thick ascending limb of the loop of Henle (2, 14-16, 29, 32-34). For example, BJP_mic was obtained from a patient who had no clinical evidence of cast nephropathy. This BJP did show low binding affinity to THP in our present study. In our tubular microperfusion study, BJP_mic did not obstruct the distal nephron of euvolemic rats. However, obstruction from cast formation in the distal nephron occurred when mild extracellular fluid depletion was created (16). In contrast, euvoelema slowed, but did not prevent, intranephronal obstruction from

Figure 8. Analysis of THP and deglycosylated THP (DGTHP). SDS-PAGE of THP (lane 1) and deglycosylated THP (lane 2) after staining of the gel with Coomassie blue demonstrated the molecular weight of deglycosylated THP decreased to ~ 66. The middle panel was a Western blot of THP (lane 1) and deglycosylated THP (lane 2), using our monoclonal antibody against human THP. This antibody recognized both native THP and deglycosylated THP and thus reacted to a peptide segment of THP. A smaller band was consistently observed below the deglycosylated THP on the Western blot, but the amount of this protein that was present was too low to be seen using Coomassie blue (first panel, lane 2). The second band of lower molecular weight identified by the monoclonal antibody was probably due to partial proteolysis of THP occurring during the enzymatic deglycosylation process. Glycoconjugate analysis was accomplished using a glycan detection kit. Carbohydrate was not detected on deglycosylated THP (DGTHP) (third panel, lane 2).

Figure 9. Change in turbidity of solutions containing THP and deglycosylated THP after addition of BJPs (n = 3 experiments). Turbidity increased when BJP_mic was added to the solution containing THP. No apparent incremental increase in turbidity was seen when BJP_mic was added to the solution containing deglycosylated THP.

Figure 10. Change in turbidity of solutions containing THP and BjP_mic, BjP_rap, and BjP_don in the presence or absence of our monoclonal antibody against human THP. Initial slopes of the aggregation curves were calculated to represent the abilities of BJPs to aggregate THP and were illustrated in parentheses. All three BJPs coaggregated with THP. This effect was partially blocked when the THP solution was preincubated with monoclonal antibody.
BJPmic, which had a higher binding affinity for THP. Thus, other factors were also important in modulating BJP–THP aggregation to produce intraluminal obstruction from cast formation. In the management of multiple myeloma, a combined consideration of all these factors should be applied to prevent renal failure.

In summary, we identified a binding site for BJP on the peptide portion of THP. Taken together with previous studies (15, 16), in the proper setting binding to THP resulted in coaggregation that ultimately produced distal nephron casts that obstructed the tubule lumen. Previously, we demonstrated that colchicine modified this binding interaction to prevent cast formation in rats (16). In the present study, reducing agents, by breaking the abundant intramolecular disulfide bonds and thus changing the tertiary conformation of THP, decreased binding and subsequent coaggregation of this protein with BJs. Cysteamine and N-acetyl-cysteine have been used clinically to treat other disorders with minor side effects (35). The possible role of reducing agents, with or without colchicine, to prevent cast nephropathy and potentially dissolve casts once they have formed in myeloma patients requires further studies.

Acknowledgments

The authors thank Dr. J. Claude Bennett and Dr. David G. Warnock for their helpful suggestions and review of this manuscript. We also thank Ms. Melinda McMorris and Mr. Brett Thorn for their technical assistance and the Media Service of the Birmingham Veterans Affairs Medical Center for the photography and illustrations. This work was supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.

References


Table III. Characteristics of BJs Used in These Studies

<table>
<thead>
<tr>
<th>Protein</th>
<th>Isotype</th>
<th>Isoelectric point (range)</th>
<th>Nephrotoxic</th>
<th>Avidity for THP</th>
</tr>
</thead>
<tbody>
<tr>
<td>BJPmy</td>
<td>κ</td>
<td>5.2, 5.3, 5.4* (5.2–6.6)</td>
<td>Yes—documented cast nephropathy</td>
<td>Highest</td>
</tr>
<tr>
<td>BJPMic</td>
<td>κ</td>
<td>7.6–7.7</td>
<td>Yes—unknown morphology</td>
<td>High</td>
</tr>
<tr>
<td>BJPhap</td>
<td>λ</td>
<td>5.6–5.7</td>
<td>Yes—distal nephron cast formation in rats (16)</td>
<td>High</td>
</tr>
<tr>
<td>BJPlam</td>
<td>κ</td>
<td>6.9–7.2</td>
<td>Yes—distal nephron cast formation in rats (15)</td>
<td>Low</td>
</tr>
<tr>
<td>BJPlam</td>
<td>κ</td>
<td>5.4* (5.2–6.5)</td>
<td>No†</td>
<td>Lowest</td>
</tr>
<tr>
<td>Albumin</td>
<td>—</td>
<td>4.8</td>
<td>No</td>
<td>Absent‡</td>
</tr>
</tbody>
</table>

* Predominant isoelectric point of the BJP. † While not nephrotoxic in the human subject and euolemic rats, this protein did cause cast formation and distal nephron obstruction in hydropenic rats (16). ‡ Demonstrated in this and previous (15, 16) studies.

Figure 11. Turbidity measurements of solutions containing THP and BJPmic in the presence or absence of dithiothreitol, 1.5 mM. Aggregation of THP induced by BJPmic was partially inhibited when dithiothreitol was added simultaneously with BJPmic.